Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Cyclacel Pharmaceuticals, Inc. (CYCC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.3200-0.2000 (-5.68%)
At close: 04:00PM EST
3.3000 -0.02 (-0.60%)
After hours: 04:49PM EST
Advertisement
Sign in to post a message.
  • G
    GERALD
    Don't worry Folks. "Spiro the Zero" is in charge.
  • C
    Chari
    Looks like the gap from year ago is closed now.
  • K
    Kevin
    I've had a small stake in this based on some of the early stage drug candidates, including (or perhaps especially) 065. When they initially reported a response with 065, was hoping this would be followed by more promising data. Esmo came and went with no promise fulfilled. But I've kept a small stake here to see what happens next. Today's events, coupled with the board appointment, make clear that 140 is now the golden child with the potential to make CYCC a BO target, similar to what happened with ARQL (which I owned from the 3's before we were bought by Merk for 20).
  • N
    NPC34287622458224938453248753
    according to ClinicalTrials.gov, the company’s CDK Inhibitor and Venetoclax study in relapsed or refractory CLL patients is expected to be completed by this Friday, May 15, 2020. This is important to keep in mind as not only did the company have great operational results, there’s likely a catalyst ahead as we hear more about this trial.
    Bullish
  • K
    Kevin
    Form 13 filed by Renaissance Technologies LLC. Not a ton of shares (a little over 1.26 million) but according to Wikipedia, RT LLC "is an American hedge fund firm based in East Setauket, New York, on Long Island, which specializes in systematic trading using quantitative models derived from mathematical and statistical analyses. The firm is widely regarded as the "most secretive and successful" hedge fund of all time.
  • S
    Sram
    CYCLACEL ANNOUNCES PRICING OF $20 MILLION PUBLIC OFFERING
    GlobeNewswire GlobeNewswire•April 21, 2020
    BERKELEY HEIGHTS, N.J., April 21, 2020 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the pricing of a public offering with expected total gross proceeds of approximately $20 million, before deducting placement agent fees and other offering expenses payable by the Company.

    Roth Capital Partners is acting as the lead placement agent for the offering. Ladenburg Thalmann and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-placement agents for the offering.

    The securities offered by the Company consist of (i) 4,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and (ii) common warrants to purchase up to 4,000,000 shares of common stock. Each share of common stock and, as applicable, each pre-funded warrant, is being sold together with a common warrant to purchase one share of common stock at a combined effective price to the public of $5.00 per share and accompanying common warrant, and/or $4.999 per pre-funded warrant and accompanying common warrant. For each pre-funded warrant the Company sells, the number of shares of common stock the Company is offering will be decreased on a one-for-one basis. The common warrants will be immediately exercisable at a price of $5.00 per share of common stock and will expire five years from the date of issuance. The shares of common stock and/or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on April 23, 2020, subject to customary closing conditions.
  • A
    Anonymous
    My first stock purchase was CYCC when it was about $4.80 years ago. I bought about 950 shares. Then...a 12-1 stock split May 2016, then another split of 20-1 this month. I now have 4 shares. I only need it to go to $1,140 to break even...$1,277 to go! Yeah...and I love paper cuts too.
  • K
    Kevin
    New form 13G filed by Pura Vida Investments; bought 475K shares at 6.40/share.
  • c
    cems70
    https://finance.yahoo.com/news/cyclacel-pharmaceuticals-announces-collaboration-university-110010988.html:
    "Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease"

    I'm not sure why this merits a 100%+ stock price runup. Cytodyn's (CYDY) Leronlimab has already demonstrated success reducing runaway inflammation associated with the cytokine storm. The drug is in phase 2b/3 trials with results expected by May 1.
  • R
    Ryan
    NTEC 3 stocks, all biotech surging that are delinquient in filing.

    You think that is a coincidence? They have to get above a dollar or set a placement for at least 20 or 40 million till the street catches on or hedge fund accumulation sends the stock surging.

    Ntec has not popped yet, like trill didn't show up on the gainers list or the trending list. Plus it's in Israel, Israeli company, they have money and launch their own public stocks all the time.

    Nabriva in Dublin, could have got their but because they had something, 2 pills for different areas and easily handled a placement= cash is now good. N B R V

    Both are not if they start to surge, only when?
  • P
    Paul
    Selling has dried up here on diminishing volume and it looks like we should get a nice pop here. With $5.21 cash per share, no debt, and a pipeline getting closer to fruition---any good news re clinicals or possible takeover interest could send this a lot higher. My opinion.
  • F
    Frank
    Pharmaceutical companies do that type of dilution lose trust of investors.
  • M
    Matt
    As a past bagholder, I learned my lesson in investing in CYCC. I sold out completely with the recent spike to $19. I usually sell too soon so I really do wish longs all the best. It will probably go up now that I'm out.
  • S
    Sram
    *Cyclacel Pharmaceuticals shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and a $17 price target.
    Benzinga
  • O
    Oblio
    So I listened to Spiro's presentation. His claim to fame currently is that Cyclacel is the only company to date with a molecule that has proven in human trials that 065 can suppress MCL1 a major cancer cell mechanism that creates resistance to already approved cancer drugs that initially work but then fail over time. The trials started at lower doses checking for toxicities and they now know that the higher doses are effective with no major toxicities. The current trials continue to build a better understanding of effective IV dose frequencies and they are now moving forwards on oral dosing. Cash run way is about one year. That's about it in a nut shell.
  • C
    C.R.E.A.M
    in @4.25 . price target of $130. all you need to know. going to load on dips but this will probably be at $5 come monday morning
    Bullish
  • C
    Chari
    I just have 200 shares here @6.25. Bought it because of Tip ranks’ article “buy these stocks before they double: says Oppenheimer…”. May be I will add more if it gets to 5’s. But I wonder if someone can offer an objective evaluation of the medium term prospects for the co. Certainly don’t want to become a bag holder. Thanks and GLTA.
  • S
    Stingray
    Had this stock for 10 years, had a boat load of shares now I have 4 shares left. Over the years all spiro does is RS and diluting your shares
  • M
    Matt
    I saw yesterday's news about the new potential indication. We've seen several of these over the years. It seems like it should be promising but then you look at the price action and no smart money appears to be jumping at the chance to by CYCC shares. That tells us all something.
  • R
    Roy
    Does anyone know what happened with Cyclacel Pharmaceuticals Announces Collaboration With the University of Edinburgh to Study Its CDK Inhibitors to Reduce Runaway Inflammation in COVID-19 Disease
Advertisement
Advertisement